InterCure Ltd. (INCR)
USD 1.6
(3.23%)
USD 1.6
(3.23%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 150.16 Million ILS | -33.92% |
| 2022 | 102.15 Million ILS | 75.81% |
| 2021 | 58.1 Million ILS | 103.04% |
| 2020 | 28.61 Million ILS | -64.94% |
| 2019 | 81.61 Million ILS | 731.96% |
| 2018 | 9.81 Million ILS | 776.56% |
| 2017 | 1.11 Million ILS | -20.07% |
| 2016 | 1.4 Million ILS | -41.3% |
| 2015 | 2.38 Million ILS | -59.57% |
| 2014 | 5.89 Million ILS | -29.3% |
| 2013 | 8.34 Million ILS | -3.52% |
| 2012 | 8.64 Million ILS | -21.23% |
| 2011 | 10.98 Million ILS | -27.28% |
| 2010 | 15.1 Million ILS | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 15.57 Million ILS | -65.26% |
| 2024 Q2 | 15.57 Million ILS | 0.0% |
| 2023 Q1 | 26.34 Million ILS | -3.96% |
| 2023 Q2 | 25.92 Million ILS | -1.6% |
| 2023 Q4 | 44.82 Million ILS | -21.37% |
| 2023 Q3 | 57 Million ILS | 119.91% |
| 2023 FY | 67.5 Million ILS | -33.92% |
| 2022 Q3 | 30.87 Million ILS | 25.0% |
| 2022 Q2 | 24.69 Million ILS | 28.96% |
| 2022 Q1 | 19.15 Million ILS | -11.1% |
| 2022 FY | 102.15 Million ILS | 75.81% |
| 2022 Q4 | 27.43 Million ILS | -11.15% |
| 2021 Q1 | 9.21 Million ILS | 16.86% |
| 2021 FY | 58.1 Million ILS | 103.04% |
| 2021 Q4 | 21.54 Million ILS | 36.08% |
| 2021 Q2 | 11.52 Million ILS | 25.09% |
| 2021 Q3 | 15.83 Million ILS | 37.41% |
| 2020 Q3 | 7.83 Million ILS | 22.6% |
| 2020 FY | 28.61 Million ILS | -64.94% |
| 2020 Q1 | 6.51 Million ILS | 58.23% |
| 2020 Q2 | 6.38 Million ILS | -1.96% |
| 2020 Q4 | 7.88 Million ILS | 0.63% |
| 2019 Q3 | 14.53 Million ILS | -2.91% |
| 2019 FY | 81.61 Million ILS | 731.96% |
| 2019 Q1 | 47.99 Million ILS | 1070.85% |
| 2019 Q2 | 14.97 Million ILS | -68.81% |
| 2019 Q4 | 4.11 Million ILS | -71.67% |
| 2018 FY | 9.81 Million ILS | 776.56% |
| 2018 Q4 | 4.09 Million ILS | 0.0% |
| 2018 Q3 | 4.09 Million ILS | 129.38% |
| 2018 Q2 | 1.78 Million ILS | 0.0% |
| 2018 Q1 | 1.78 Million ILS | 18.53% |
| 2017 Q4 | 1.5 Million ILS | -0.0% |
| 2017 Q3 | 1.5 Million ILS | 66.54% |
| 2017 Q1 | 939.88 Thousand ILS | 145.59% |
| 2017 Q2 | 905.21 Thousand ILS | -3.69% |
| 2017 FY | 1.11 Million ILS | -20.07% |
| 2016 Q2 | 320.04 Thousand ILS | -0.41% |
| 2016 Q1 | 321.34 Thousand ILS | -39.44% |
| 2016 FY | 1.4 Million ILS | -41.3% |
| 2016 Q4 | 382.7 Thousand ILS | -1.04% |
| 2016 Q3 | 386.7 Thousand ILS | 20.83% |
| 2015 FY | 2.38 Million ILS | -59.57% |
| 2015 Q3 | 636.51 Thousand ILS | 15.34% |
| 2015 Q2 | 551.83 Thousand ILS | -14.96% |
| 2015 Q1 | 648.91 Thousand ILS | 26.07% |
| 2015 Q4 | 530.59 Thousand ILS | -16.64% |
| 2014 Q3 | 1.07 Million ILS | -46.5% |
| 2014 Q2 | 2 Million ILS | -2.31% |
| 2014 Q1 | 2.05 Million ILS | 198.62% |
| 2014 FY | 5.89 Million ILS | -29.3% |
| 2014 Q4 | 514.71 Thousand ILS | -52.01% |
| 2013 Q4 | 687.16 Thousand ILS | -61.4% |
| 2013 FY | 8.34 Million ILS | -3.52% |
| 2013 Q3 | 1.78 Million ILS | -38.3% |
| 2013 Q2 | 2.88 Million ILS | -7.74% |
| 2013 Q1 | 3.12 Million ILS | 16.14% |
| 2012 Q1 | 2.17 Million ILS | 179.3% |
| 2012 Q2 | 2.19 Million ILS | 1.02% |
| 2012 Q3 | 1.43 Million ILS | -34.8% |
| 2012 Q4 | 2.69 Million ILS | 87.82% |
| 2012 FY | 8.64 Million ILS | -21.23% |
| 2011 FY | 10.98 Million ILS | -27.28% |
| 2011 Q3 | -2.74 Million ILS | 0.0% |
| 2011 Q1 | -2.74 Million ILS | 27.28% |
| 2011 Q2 | -2.74 Million ILS | 0.0% |
| 2011 Q4 | -2.74 Million ILS | 0.0% |
| 2010 Q4 | -3.77 Million ILS | 0.0% |
| 2010 Q1 | -3.77 Million ILS | 0.0% |
| 2010 Q3 | -3.77 Million ILS | 0.0% |
| 2010 FY | 15.1 Million ILS | 0.0% |
| 2010 Q2 | -3.77 Million ILS | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 23.378% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | -234.791% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 5.679% |
| Cosmos Health Inc. | 26.18 Million USD | -473.577% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -613.65% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 44.771% |
| Cronos Group Inc. | 96.7 Million USD | -55.277% |
| Incannex Healthcare Limited | 30.05 Million USD | -399.674% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -283.539% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | -206.226% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -3662.511% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -1044.176% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -1044.176% |
| SCYNEXIS, Inc. | 51.84 Million USD | -189.629% |
| Safety Shot Inc | 12.1 Million USD | -1140.056% |
| Theratechnologies Inc. | 72.75 Million USD | -106.398% |
| Alpha Teknova, Inc. | 45.85 Million USD | -227.454% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -984.872% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 53.99% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -1489.742% |
| Dynavax Technologies Corporation | 219.14 Million USD | 31.476% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 35.307% |
| Radius Health, Inc. | 265.92 Million USD | 43.531% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -4792.727% |
| Alvotech | 285.43 Million USD | 47.391% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 74.548% |
| SIGA Technologies, Inc. | 22.04 Million USD | -581.245% |
| Shineco, Inc. | 17.94 Million USD | -736.676% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -19594.239% |
| Journey Medical Corporation | 54.59 Million USD | -175.061% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -743.231% |
| Embecta Corp. | 528.4 Million USD | 71.581% |
| Harrow Health, Inc. | 89.97 Million USD | -66.902% |
| Procaps Group, S.A. | 199.47 Million USD | 24.72% |
| Biofrontera Inc. | 39.95 Million USD | -275.803% |
| DURECT Corporation | 43.71 Million USD | -243.514% |
| PainReform Ltd. | 9.58 Million USD | -1466.851% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 71.614% |
| OptiNose, Inc. | 85.1 Million USD | -76.455% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 1670.62% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 52.197% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -248.897% |
| ProPhase Labs, Inc. | 37.85 Million USD | -296.721% |
| Phibro Animal Health Corporation | 260.29 Million USD | 42.31% |
| Procaps Group S.A. | 187.24 Million USD | 19.802% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -1428.417% |
| Viatris Inc. | 5.96 Billion USD | 97.483% |
| Rockwell Medical, Inc. | 15.37 Million USD | -876.759% |
| Aytu BioPharma, Inc. | 59.84 Million USD | -150.948% |
| Tilray Brands, Inc. | 251.35 Million USD | 40.257% |
| PetIQ, Inc. | 192.72 Million USD | 22.082% |
| Talphera, Inc. | 11.99 Million USD | -1152.018% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 90.594% |
| Alimera Sciences, Inc. | 62.64 Million USD | -139.726% |
| Assertio Holdings, Inc. | 368.58 Million USD | 59.259% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -2451.443% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 8.971% |
| Hempacco Co., Inc. | 7.59 Million USD | -1876.805% |
| Alvotech | 285.43 Million USD | 47.391% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 56.461% |
| Kamada Ltd. | 45.42 Million USD | -230.575% |
| Currenc Group, Inc. | 24 Million USD | -525.641% |
| Indivior PLC | 911 Million USD | 83.516% |
| Evoke Pharma, Inc. | 12.4 Million USD | -1110.083% |
| Flora Growth Corp. | 10.57 Million USD | -1319.482% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -613.65% |
| Evolus, Inc. | 189.75 Million USD | 20.864% |
| HUTCHMED (China) Limited | 436.23 Million USD | 65.576% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 2.574% |
| Akanda Corp. | 3.48 Million USD | -4210.798% |